{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-24-000098","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.235550+00:00","generated_at":"2026-05-30T04:38:58.189586+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Praxis Q3 net loss $51.9M; relutrigine seizure freedom; ulixacaltamide interim Q1 2025","bullets":["Cash and equivalents $411.2M at Sep 30, 2024, up from $81.3M at Dec 31, 2023; net loss $51.9M vs $24.6M prior year Q3.","Relutrigine (PRAX-562): 46% placebo-adjusted seizure reduction in EMBOLD cohort 1; 30% of patients (5/15) achieved seizure freedom; registrational cohort 2 initiated.","Ulixacaltamide: interim analysis for Phase 3 Essential3 Study 1 expected Q1 2025; NDA filing anticipated in 2025; Parkinson's program to re-initiate.","Vormatrigine (PRAX-628): RADIANT topline in H1 2025 and POWER1 topline in H2 2025; pain expansion being evaluated.","R&D expenses $41.9M (up $24.6M); G&A $15.3M (up $6.6M); stock-based compensation $12.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-24-000098","json":"https://secwatch.observer/filing/0001689548-24-000098.json","markdown":"https://secwatch.observer/filing/0001689548-24-000098.md","text":"https://secwatch.observer/filing/0001689548-24-000098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000098/0001689548-24-000098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000098/prax-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:38:58.189586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}